Table 1: Prognostic factors for secondary cytoreductive surgery in recurrent ovarian cancer (univariate analyses for variables at recurrence).
Characteristic | Median survival Onda, et al. [15] | Median survival Eisenkop, et al. [16] | Median survival Zang, et al. [18] |
No. of patients | 44 | 87 | 117 |
DFI (months) | |||
3-12 | 18 | ||
13-23 | 26 | ||
≥ 24 | 40 | ||
< 12 | 23 | ||
≥ 12 | 47 | ||
6-12 | 25 | ||
13-36 | 44.4 | ||
> 36 | 56.8 | ||
Largest recurrence | |||
≤ 10 cm | 37.3 | ||
> 10 cm | 35.6 | ||
< 6 cm | 40 | NA | |
≥ 6 cm | 14 | ||
No. of recurrent tumours | |||
Solitary | 64 | NA | NS |
Multiple | 27 | ||
Liver metastasis | |||
Absent | 33 | NA | NA |
Present | 20 | ||
Cytoreductive outcome | |||
Visibly disease free | 55 | 44.4 | |
Not visibly disease free | 22 | 19.3 | |
0 cm | _b | ||
≤ 1 cm | 26 | ||
> 1 cm | 14.5 | ||
Ascite | |||
No | NA | 35.9 | 25.5 |
Yes | 35.6 | 17.5 | |
ECOG performance status | |||
0 | NS | NS | 40.5 |
1 | 24.5 | ||
2 | 15.0 |
DFI: Disease free interval; ECOG: Eastern cooperative oncology group; NA: Not analysed, NS: Not significant, _b: The median survival was not reached.